Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2010-01-15
2011-12-20
Tsang, Cecilia (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018500, C514S018300, C514S021300, C530S345000
Reexamination Certificate
active
08080519
ABSTRACT:
Pharmaceutical agents, compositions containing the same and methods for their use for enhancing the bioavailability and pharmacological efficacy of therapeutic peptides. The pharmaceutical agents have the formulain-line-formulae description="In-line Formulae" end="lead"?Carrier-Linker-Peptidein-line-formulae description="In-line Formulae" end="tail"?Wherein Peptide is a therapeutically active peptide species having the formula aanwherein n is the number of amino acid residues in the peptide and n is 2 to 40, Carrier is benzoyl, phenylacetyl, cinnamoyl, 3-OH-cinnamoyl, 3,4-OH-cinnamoyl, 3,4-dimethoxycinnamoyl, 3,4-methylenedioxycinnamoyl, 3-methoxycinnamoyl, 3,4-diethoxy-cinnamoyl, 3,4,5-trimethoxy-cinnamoyl, t-butoxycarbonyl, benzyloxycarbonyl, pivaloyl, N-9-fluorenylmethoxycarbonyl, fumaroyl and derivatives thereof and Linker is a C6 to C16 lipidic chain or a derivative thereof, an 8-amino-3,6-dioxaoctanoic acid or polymeric derivative thereof, pseudo peptide, or peptide mimic. Methods of use of compositions having the formula Carrier-Peptide wherein Carrier and Peptide are as just defined are also disclosed.
REFERENCES:
patent: 4239754 (1980-12-01), Sache
patent: 4336534 (1982-06-01), Kumagai
patent: 4339534 (1982-07-01), Johansen
patent: 4396606 (1983-08-01), Goldstein
patent: 4694006 (1987-09-01), Bundgaard
patent: 4925673 (1990-05-01), Steiner
patent: 4335119 (1992-07-01), Johnsen et al.
patent: 5212158 (1993-05-01), Fiez Vandai
patent: 5624894 (1997-04-01), Bodor
patent: 6136952 (2000-10-01), Li
patent: 6908900 (2005-06-01), Zimmer
patent: 7671029 (2010-03-01), Zimmer
patent: 2002/0090603 (2002-07-01), Lipton
patent: 2003/0060413 (2003-03-01), Zimmer
patent: 2004/0186058 (2004-09-01), Zimmer
patent: WO 98/11126 (1998-03-01), None
Bernatowicz et al.,J. Med. Chem. 39:4879-87 (1996).
Fukushima, K.J. Med. Sci. v71(6):727-43 (1996).
Vergnolle, N., et al.P.N.A.S. v95:7766-71 (1998).
Langguth, P., et al.J. Controlled Releasev46(1):39-57 (1997).
Egleton, R.D., et al.Brain Res. v881(1):37-46 (2000).
Pauletti, G.M., et al.Adv. Drug Deliv. Rev. v27(2-3):235-56 (1997).
Ahlers et al.P.N.A.S. v94:10856-61 (1997).
Greenstein et al.J. Immunol. v148:3970-77 (1992).
Belyakov et al.J. Clin. Investig. v102(12):2072-81 (1998).
Patel et al.FEBS lett. v62(1):60-63 (1976).
Hashimoto et al.Endocrinol. v26(1):103-109 (1979).
Belyakov, et al.,Proc. Natl Acad. Sci. USA, 1998, 95(4):1709-14.
Fukushima, K., Hypoglycemic Effect and Enhanced Gastrointestinal Absorption of Insulin Using New Cinnamoyl-phenylalanine Derivatives, Hokkaido Journal of Medical Science, vol. 71, No. 6, 1996, pp. 727-743.
Vergnolle, N., et al., Proteinase-Activated Receptor 2 (PAR2)-Activating Peptides: Identification of A Receptor Distinct From PAR2) That Regulates Intestinal, Transport, Proceedings of the National Academy of Sciences of USA, national Academy of Science, vol. 95, Jun. 1998, pp. 7766-7771.
Langguth, P., et al., The Challenge of Proteolytic Enzymes in Intestinal Peptide Delivery, Journal of Controlled Release, Elsevier Science Publishers B.V. Amsterdam, NL, vol. 46, No. 1, May 1997, pp. 39-57.
Egleton, R.D., et al., Improved Bioavailability to the Brain of Glycosylated Mat-Enkephalin Analogs, Brain Research, vol. 881, No. 1, 2000, pp. 37-46.
Pauletti, G.M., et al., Improvement of Oral Peptide Bioavailability: Peptidomimetics and Prodrug Strategies, Advanced Drug Delivery Review, vol. 27, No. 203, 1997, pp. 235-256.
Ahlers, et al., Enhanced Immunogenicity of HIV-1 Vaccine Construct by Modification of the Native Peptide Sequence, Proc. Natl. Acad. Sci. USA, vol. 94, pp. 10856-10861, Sep. 1997.
Greenstein, et al., A Universal T Cell Epitope-Containing Peptide From Hepatitis B Surface Antigen Can Enhance Antibody Specific for HIV gp120, Journal of Immunology, vol. 148, pp. 3970-3977, No. 12, Jun. 1992.
Belyakov, et al., The Importance of Local Mucosal HIV-Specific CD8* Cytotoxic T Lymphocytes for Resistance to Mucosal Viral Transmission in Mice and Enhancement of Resistance by Local Administration of IL-12, The Journal of Clinical Investigation, vol. 102(12); pp. 2072-2081, Dec. 1998.
Belyakov, et al., Mucosal Immunization With HIV-1 Peptide Vaccine Induces Mucosal and Systemic Cytotoxic T Lymphocytes and Protective Immunity in Mice Against Intrarectal Recombinant HIV—Vaccinia Challenge, Proc. Natl. Acad. Sci. USA, vol. 95, pp. 1709-1714, Feb. 1998.
Patel, et al., Oral Administration of Insulin by Encapsulation within Liposomes, North-Holland Publishing Company, vol. 62, No. 1, pp. 60-63, Feb. 1976.
Hashimoto, et al., ACTH Release in Pituitary Cell Cultures, Effect of Neurogenetic Peptides and Neurotransmitter Substances Corticotropin Releasing Factor (CRF), Endocrinol. Japan, vol. 26(1), pp. 103-109, Feb. 1979.
Bernatowicz et al., Development of Potent Thrombin Receptor Antagonist peptides,J. Med. Chem. 1996, 39:4879-87.
U.S. Appl. No. 09/844,426, filed Aug. 7, 2000.
ImmuPharma SA (France)
McCarter & English LLP
Teller Roy
Tsang Cecilia
LandOfFree
Compositions and methods for enhanced pharmacological... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for enhanced pharmacological..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for enhanced pharmacological... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4263761